PRM#18
IRFMNi002-B
General
Cell Line |
|
hPSCreg name | IRFMNi002-B |
Cite as: | IRFMNi002-B (RRID:CVCL_UJ77) |
Alternative name(s) |
PRM#18
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
|
Last update | 4th August 2022 |
User feedback | |
Provider |
|
Generator | IRCCS - Istituto di Ricerche Farmacologiche Mario Negri (IRFMN) |
Owner | IRCCS - Istituto di Ricerche Farmacologiche Mario Negri (IRFMN) |
External Databases |
|
BioSamples | SAMEA4975314 |
Cellosaurus | CVCL_UJ77 |
Wikidata | Q94323817 |
General Information |
|
Publications | |
* Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
Sex | female |
Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
Yes
|
Donor Relations |
|
Other cell lines of this donor | |
External Databases (Donor) |
|
BioSamples | SAMEA4914697 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent expressly prevent the derivation of pluripotent stem cells? | No |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | Yes |
How may genetic information associated with the cell line be accessed? | No information |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | Comitato Etico di Bergamo |
Approval number | 113/17 |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | Comitato Etico di Bergamo |
Approval number | 113/17 |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
A leukocyte with a single non-segmented nucleus in the mature form found in the circulatory pool of blood.
|
Source cell origin |
A fluid that is composed of blood plasma and erythrocytes.
Synonyms
|
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Sendai virus |
Genes | |
Is reprogramming vector detectable? |
Yes |
Methods used |
PCR
|
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method |
Enzymatically
Accutase
|
Medium |
mTeSR™ 1
|
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
NANOG |
Yes |
|
|
|||
POU5F1 (OCT-4) |
Yes |
|
|
|||
SOX2 |
Yes |
|
||||
SSEA-3 |
Yes |
|
||||
SSEA-4 |
Yes |
|
||||
TRA 1-60 |
Yes |
|
||||
TRA 1-81 |
Yes |
|
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.